Program

Life Science

The Life Science team develops new technologies to improve people’s well-being and health through light. Our most recent activities are in the field of photobiomodulation — the utilization of red and near-infrared light to trigger photochemical effects in cells. These photochemical effects can cause a major positive impact on people's health and well-being.

Seaborough Life Science

Seaborough Life Science invents and develops lighting technologies to improve people’s well-being and health. We develop materials to enable novel light therapies to treat skin diseases and we conduct groundbreaking long-term research in the field of photobiomodulation.

Light & health

Light is a vital source for life and for human health and well-being, just like food, water and air. The human body – and in particular the skin and the eyes – interacts with light in many different ways. Sunlight is essential for vitamin D3 generation in the skin, and is associated with many health aspects like blood pressure and bone strength. Light also strongly influences our circadian rhythm, which helps us sleep, and helps us recover well, both physically and mentally.

Light therapy can be used to treat skin disorders, such as psoriasis, acne, eczema and neonatal jaundice. Light can also be used effectively to treat and prevent seasonal affective disorder, and potentially other psychiatric disorders too.

Our current technology

Our currently running ground-breaking research program is focused on the photobiomodulation effect. Many scientists have already reported the pain reducing and accelerated wound healing effects of red and near-infrared light, which is thought to originate from activation of the mitochondria in human (skin) cells. Our hypothesis goes beyond local effects on exposed skin, as we are investigating many more health, performance, and well-being indicators in our current clinical trial.

With a proven hypothesis of systemic photobiomodulation, we  develop the technological solutions to include the right wavelengths and intensity in everyday products, to deliver great health effects to people spending most of their time indoors. Our highly skilled engineers will make sure we will develop the most energy efficient and sustainable products possible.

Building on the expertise of our staff and (scientific) collaborators, Seaborough is constantly looking for new technologies in the field of lighting that contribute to human health and well-being.

Our People

Mike Krames

Senior Advisor

Mike is a recognized world authority on visible-spectrum LEDs and their applications for lighting and displays, with more than 20 years of experience in both startups and large companies in the LED industry. He is currently President and Founder of Arkesso, LLC, based in Silicon Valley, California.  Previously, he was Chief Technology Officer at Soraa, Inc., an LED product company founded by Nobel Prize winner Shuji Nakamura.  Prior to that, he was Executive Vice President at Philips Lumileds, where he ran the Advanced Laboratories and pioneered programs in LEDs and luminescence, focusing on materials, devices, and systems for applications to lighting and displays. He has served on numerous roundtables and panels for the U.S. Department of Energy and Basic Energy Sciences. He is an IEEE Fellow, IES Fellow and Chair of the SPIE Photonics West Conference on Light-Emitting Diodes.

He has been an advisor to Seaborough since 2015, where he is supporting technical and intellectual property development, project management, business development and the establishment of new partnerships.

Anne Berends

Program Director Life Science

Anne likes to work in a dynamic and multidisciplinary team and that is exactly what she found in the Life Science program at Seaborough. Translating fundamental scientific insights to products that improve human wellbeing and health, require skills and insights from so many viewing angles that true teamwork is a must. Being challenged and achieving ambitious goals with a team is where Anne gets her energy from, both at work and outside, at a rowing course.

What we are working on

2020
Clinical trial
2020
Prototype
2021
Clinical trial
2021
Market-ready prototype